nsclc 2nd line
DESCRIPTION
TRANSCRIPT
Second Line Treatment of metastatic Non-Small Cell
Lung Cancer
Update from the World Conference on Lung Cancer
G. Nsouli MD
Tuesday, August 9, 2011
Tuesday, August 9, 2011
Tuesday, August 9, 2011
Tuesday, August 9, 2011
Weekly vs 3-weekly Docetaxel
Individual Patient Data Meta-Analysis of Docetaxel Administered Once Every 3 Weeks Compared With OnceEvery Week Second-Line Treatment of Advanced Non–Small-Cell Lung Cancer Di Maio J.Clin. Oncol.2007;25:1377-82
Overall survival (OAS) curves by treatment arm.
Tuesday, August 9, 2011
Treatment effect on survival within major patient subgroups. PS,performance status.
Individual Patient Data Meta-Analysis of Docetaxel Administered Once Every 3 Weeks Compared With OnceEvery Week Second-Line Treatment of Advanced Non–Small-Cell Lung Cancer Di Maio J.Clin. Oncol.2007;25:1377-82
Weekly vs 3-weekly Docetaxel
Tuesday, August 9, 2011
Pemetrexed vs. Docetaxel in second line
Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung CancerPreviously Treated With ChemotherapyJ. Clin. Oncol 2004; 22:1589-97
Tuesday, August 9, 2011
Survival and Toxicity
Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung CancerPreviously Treated With ChemotherapyJ. Clin. Oncol 2004; 22:1589-97
Tuesday, August 9, 2011
Elderly Patients Benefit From Second-Line CytotoxicChemotherapy: A Subset Analysis of a Randomized PhaseIII Trial of Pemetrexed Compared With Docetaxel inPatients With Previously Treated Advanced Non–Small-Cell Lung Cancer Weiss G J.Clin. Oncol. 006;24:4405-11
Median time to progression (A) for patients younger than 70 years of age:pemetrexed, 3.0 months v docetaxel, 3.9 months (hazard ratio [HR], 1.03; ; (B) for patients 70 years of age: pemetre-xed, 4.6 months vdocetaxel, 2.9 months (HR, 0.72;
Tuesday, August 9, 2011
Elderly Patients Benefit From Second-Line CytotoxicChemotherapy: A Subset Analysis of a Randomized PhaseIII Trial of Pemetrexed Compared With Docetaxel inPatients With Previously Treated Advanced Non–Small-Cell Lung Cancer Weiss G J.Clin. Oncol. 006;24:4405-11
Median overall survival time (A) for patients younger than 70 years of age:pemetrexed, 7.8 months v docetaxel, 8.0 months HR], 1.02; (B) for patients 70 years of age: pemetrexed, 9.5 months v docetaxel, 7.7 months (HR, 0.86;
Tuesday, August 9, 2011
Current Guidelines in Second line treatment of NSCLC
• For patients with disseminated metastatic disease, both second-line cytotoxic chemotherapy and small molecule epidermal growth factor receptor (EGFR) inhibitors may provide palliation and increase survival.
• When symptoms are due to progressive disease within the chest or from metastatic involvement of a single or limited number of sites, radiation therapy (RT) is often useful for palliation.
Tuesday, August 9, 2011
Tuesday, August 9, 2011
Tuesday, August 9, 2011
Tuesday, August 9, 2011
Tuesday, August 9, 2011
Tuesday, August 9, 2011
Tuesday, August 9, 2011
Tuesday, August 9, 2011
Tuesday, August 9, 2011
Tuesday, August 9, 2011
Tuesday, August 9, 2011
Tuesday, August 9, 2011
Tuesday, August 9, 2011
Tuesday, August 9, 2011
Tuesday, August 9, 2011
Tuesday, August 9, 2011
Tuesday, August 9, 2011
Tuesday, August 9, 2011
Tuesday, August 9, 2011
Tuesday, August 9, 2011
Tuesday, August 9, 2011
Tuesday, August 9, 2011
Tuesday, August 9, 2011
Tuesday, August 9, 2011
Tuesday, August 9, 2011
Tuesday, August 9, 2011
Tuesday, August 9, 2011
Tuesday, August 9, 2011
Tuesday, August 9, 2011
Tuesday, August 9, 2011
Tuesday, August 9, 2011
Tuesday, August 9, 2011
Tuesday, August 9, 2011